Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

Inclusion Criteria: * 18 years of age or older * Male or female * Chronic lymphoproliferative disease with related biology or similar clinical pattern to B-Cell Leukemia (CLL)including: small lymphocytic lymphoma (SLL), T cell prolymophocytic leukemia (T-PLL), B cell prolymphocytic leukemia (B-PLL), mantle cell lymphoma or other non-Hodgkins lymphoma in leukemic phase (peripheral blood circulating malignant cells present), Waldenstrom's macroglobulinemia * Must have relapsed from or be refractory to prior therapeutic regimens * Patients with CLL or SLL must have received at least one prior purine analogue-based chemotherapy regimen (eg, fludarabine, pentostatin or cladribine) * If previously treated with an anthracycline, anthracenedione, or trastuzumab, must have left ventricular ejection fraction \> 50% * ECOG performance status 0-2 * Life expectancy 3 months or greater Exclusion Criteria: * Pregnant or lactating women * Active 2nd malignancy or history of another malignancy within 2 years, except:treated, non-melanoma skin cancer,treated breast or cervical carcinoma in situ,or resected T1a or b prostate cancer * Chemotherapeutic agents within 4 weeks prior to study * High dose CTX with stem cell support within 6 months prior to study * Signal transduction inhibitors,or monoclonal antibodies within 4 weeks prior to study * Immunotherapy or biological response modifiers within 4 weeks prior to study * Systemic hormonal therapy within 4 weeks prior to study * Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study * Radiotherapy within 4 weeks prior to study * Active autoimmune disorder * Central nervous system or leptomeningeal involvement * Clinically significant cardiovascular disease * Known HIV infection * Serious/active infection * Surgical procedure within 2 weeks